ASH 43rd (2001)

Title Content type
CAMPATH-1H Reduces the Risk of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation and Minimally Myelosuppressive Conditioning Treatment with Low Dose Total Body Irradiation and Cyclosporine/Mycophenolate Mofetil Immuno (click for details)
Radioimmunotherapy (RAIT) with 131-Iodine Labeled Rituximab in Patients with B Cell NHL in a Myeloablative and Non-Myeloablative Regimen. (click for details)
Early and Late Infectious Complications Following Unrelated Cord Blood Transplantation (UCBT). (click for details)
Autologous Stem Cell Transplants Combined with Rituximab for Relapsed Follicular Lymphoma Achieve Prolonged Clinical and Molecular Remissions. (click for details)
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis. (click for details)
Elderly Patients with Aggressive Non-Hodgkin's Lymphoma (NHL): An Age Adjusted High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) Allows an Adequate PBPC Yield with Low Toxicity and Promising Results. (click for details)
Post-Transplant Thrombotic Thrombocytopenic Purpura (TTP), a Complication of High Risk Myeloablative and Non-Myeloablative Transplantation, Is Not Associated with von Willebrand Factor-Cleaving Protease (vWF-CP) Deficiency. (click for details)
Stem Cell Transplantation (SCT) after Successful Therapy with Glivec(STI571) for Poor-Prognosis Ph1-Positive (Ph1+) Malignancies. (click for details)
Autologous Cord Blood Infusion for Severe Aplastic Anemia (SAA). (click for details)
Yield of Surveillance Blood Cultures in Patients on Corticosteroids for Graft-Versus-Host Disease. (click for details)

Pages

Subscribe to ASH 43rd (2001)